RS66556B1 - Supstituisana 3-((3-aminofenil)amino)piperidin-2,6-dion jedinjenja, njihove kompozicije i postupci lečenja koji ih koriste - Google Patents
Supstituisana 3-((3-aminofenil)amino)piperidin-2,6-dion jedinjenja, njihove kompozicije i postupci lečenja koji ih koristeInfo
- Publication number
- RS66556B1 RS66556B1 RS20250148A RSP20250148A RS66556B1 RS 66556 B1 RS66556 B1 RS 66556B1 RS 20250148 A RS20250148 A RS 20250148A RS P20250148 A RSP20250148 A RS P20250148A RS 66556 B1 RS66556 B1 RS 66556B1
- Authority
- RS
- Serbia
- Prior art keywords
- compound
- examples
- formula
- mmol
- solvent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782298P | 2018-12-19 | 2018-12-19 | |
| US201962879900P | 2019-07-29 | 2019-07-29 | |
| PCT/US2019/067088 WO2020132014A1 (en) | 2018-12-19 | 2019-12-18 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
| EP19901383.0A EP3897636B1 (en) | 2018-12-19 | 2019-12-18 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS66556B1 true RS66556B1 (sr) | 2025-03-31 |
Family
ID=71098067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20250148A RS66556B1 (sr) | 2018-12-19 | 2019-12-18 | Supstituisana 3-((3-aminofenil)amino)piperidin-2,6-dion jedinjenja, njihove kompozicije i postupci lečenja koji ih koriste |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US11149007B2 (https=) |
| EP (2) | EP4494711A3 (https=) |
| JP (2) | JP7494181B2 (https=) |
| KR (2) | KR102866144B1 (https=) |
| CN (2) | CN113453681B (https=) |
| AU (1) | AU2019403207B2 (https=) |
| BR (1) | BR112021011968A2 (https=) |
| CA (1) | CA3124130A1 (https=) |
| CL (1) | CL2021001665A1 (https=) |
| CO (1) | CO2021007973A2 (https=) |
| DK (1) | DK3897636T3 (https=) |
| ES (1) | ES3009308T3 (https=) |
| FI (1) | FI3897636T3 (https=) |
| HR (1) | HRP20250095T1 (https=) |
| HU (1) | HUE070506T2 (https=) |
| IL (1) | IL284223B2 (https=) |
| LT (1) | LT3897636T (https=) |
| MX (1) | MX2021007473A (https=) |
| MY (1) | MY205718A (https=) |
| PE (1) | PE20212247A1 (https=) |
| PL (1) | PL3897636T3 (https=) |
| PT (1) | PT3897636T (https=) |
| RS (1) | RS66556B1 (https=) |
| SG (1) | SG11202106507RA (https=) |
| SI (1) | SI3897636T1 (https=) |
| SM (1) | SMT202500111T1 (https=) |
| TW (1) | TWI820276B (https=) |
| WO (1) | WO2020132014A1 (https=) |
| ZA (1) | ZA202104200B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113473987B (zh) | 2018-12-19 | 2024-09-03 | 细胞基因公司 | 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法 |
| CN113453681B (zh) * | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CR20220630A (es) | 2020-05-09 | 2023-01-23 | Arvinas Operations Inc | Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo |
| KR20230027066A (ko) * | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| JP7778095B2 (ja) * | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| KR20230027214A (ko) | 2020-06-24 | 2023-02-27 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| AU2021311245A1 (en) * | 2020-07-21 | 2023-03-09 | Ubix Therapeutics, Inc. | Compound for androgen receptor degradation, and pharmaceutical use thereof |
| US20240025863A1 (en) | 2020-09-16 | 2024-01-25 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022087335A1 (en) | 2020-10-23 | 2022-04-28 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| CN117203196A (zh) | 2020-12-14 | 2023-12-08 | 拜欧斯瑞克斯公司 | Pde4降解剂、药物组合物和治疗应用 |
| BR112023018839A2 (pt) * | 2021-03-17 | 2023-12-26 | Medshine Discovery Inc | Composto de glutarimida substituído por anel fundido com furano |
| KR20240026946A (ko) * | 2021-06-25 | 2024-02-29 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| WO2022272061A1 (en) * | 2021-06-25 | 2022-12-29 | Celgene Corporation | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| CN117561249A (zh) * | 2021-06-25 | 2024-02-13 | 细胞基因公司 | Cereblon结合化合物、其组合物及其用于治疗的方法 |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| CN120152718A (zh) * | 2022-11-09 | 2025-06-13 | 百时美施贵宝公司 | 用取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物的组合疗法 |
| TW202535392A (zh) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮 |
| WO2025235600A1 (en) * | 2024-05-07 | 2025-11-13 | Bristol-Myers Squibb Company | Processes for the preparation of substituted 3-((3-aminophenyl)amino) piperidine-2,6-dione compounds |
| WO2025235577A1 (en) | 2024-05-09 | 2025-11-13 | Bristol-Myers Squibb Company | Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds |
| CN118993935B (zh) * | 2024-10-23 | 2025-02-14 | 江苏恒瑞医药股份有限公司 | 咪唑啉衍生物或其盐的制备方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4302485A1 (de) | 1993-01-29 | 1994-08-04 | Merck Patent Gmbh | Piperazinderivate |
| HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| FR2768728B1 (fr) | 1997-09-19 | 1999-12-03 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique |
| FR2768729A1 (fr) | 1997-09-19 | 1999-03-26 | Rhodia Chimie Sa | Procede d'acylation d'un compose aromatique et complexes catalytiques |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| US8470829B2 (en) * | 2004-09-09 | 2013-06-25 | Chugai Seiyaku Kabushiki Kaisha | Imidazolidine derivative and use thereof |
| WO2007073432A2 (en) | 2005-10-11 | 2007-06-28 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| US20080064876A1 (en) * | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| AU2010273220B2 (en) | 2009-07-13 | 2015-10-15 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| RU2434851C1 (ru) | 2010-07-22 | 2011-11-27 | Александр Васильевич Иващенко | Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| EP2683694B1 (en) * | 2011-03-10 | 2016-04-27 | Suzhou Kintor Pharmaceuticals, Inc. | Androgen receptor antagonists and uses thereof |
| US20140112922A1 (en) | 2011-03-28 | 2014-04-24 | Cornell University | Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes |
| KR102668696B1 (ko) | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2014036897A1 (zh) * | 2012-09-04 | 2014-03-13 | 上海恒瑞医药有限公司 | 咪唑啉类衍生物、其制备方法及其在医药上的应用 |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| RU2683788C2 (ru) | 2013-01-31 | 2019-04-02 | Вертекс Фармасьютикалз Инкорпорейтед | Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов |
| RU2738833C9 (ru) | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RU2557235C1 (ru) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| EP3270917A4 (en) | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN110167556A (zh) | 2016-07-08 | 2019-08-23 | 詹森药业有限公司 | 用于治疗癌症的硫代乙内酰脲雄性激素受体拮抗剂 |
| TWI739888B (zh) | 2016-10-07 | 2021-09-21 | 美商陶氏農業科學公司 | 農藥組合物及方法 |
| CN110506039A (zh) | 2016-10-11 | 2019-11-26 | 阿尔维纳斯股份有限公司 | 用于雄激素受体靶向降解的化合物和方法 |
| US10925868B2 (en) | 2016-11-10 | 2021-02-23 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use |
| WO2018098280A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| AU2017378943B2 (en) | 2016-12-19 | 2020-06-18 | Abbisko Therapeutics Co., Ltd. | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof |
| IL312367A (en) | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN109422725A (zh) | 2017-09-04 | 2019-03-05 | 北京美倍他药物研究有限公司 | 前列腺癌治疗药物 |
| ES2959954T3 (es) | 2017-11-28 | 2024-02-29 | Aarti Pharmalabs Ltd | Proceso para la preparación de enzalutamida utilizando un nuevo intermedio |
| EP3720281A4 (en) | 2017-12-05 | 2021-05-26 | Dow Agrosciences LLC | PESTICIDE COMPOSITIONS AND PROCEDURES |
| CN114835729B (zh) | 2018-05-30 | 2024-05-31 | 江苏豪森药业集团有限公司 | 含三并环类衍生物抑制剂、其制备方法和应用 |
| CN109651256A (zh) | 2018-11-20 | 2019-04-19 | 上海健康医学院 | 一种式（viii）的恩杂鲁胺的制备方法 |
| CN113453681B (zh) * | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| CN113473987B (zh) | 2018-12-19 | 2024-09-03 | 细胞基因公司 | 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法 |
-
2019
- 2019-12-18 CN CN201980092358.2A patent/CN113453681B/zh active Active
- 2019-12-18 PE PE2021000924A patent/PE20212247A1/es unknown
- 2019-12-18 RS RS20250148A patent/RS66556B1/sr unknown
- 2019-12-18 BR BR112021011968-0A patent/BR112021011968A2/pt unknown
- 2019-12-18 HU HUE19901383A patent/HUE070506T2/hu unknown
- 2019-12-18 DK DK19901383.0T patent/DK3897636T3/da active
- 2019-12-18 MX MX2021007473A patent/MX2021007473A/es unknown
- 2019-12-18 CN CN202411325996.3A patent/CN119219606A/zh active Pending
- 2019-12-18 WO PCT/US2019/067088 patent/WO2020132014A1/en not_active Ceased
- 2019-12-18 ES ES19901383T patent/ES3009308T3/es active Active
- 2019-12-18 AU AU2019403207A patent/AU2019403207B2/en active Active
- 2019-12-18 PT PT199013830T patent/PT3897636T/pt unknown
- 2019-12-18 CA CA3124130A patent/CA3124130A1/en active Pending
- 2019-12-18 LT LTEPPCT/US2019/067088T patent/LT3897636T/lt unknown
- 2019-12-18 SM SM20250111T patent/SMT202500111T1/it unknown
- 2019-12-18 FI FIEP19901383.0T patent/FI3897636T3/fi active
- 2019-12-18 TW TW108146514A patent/TWI820276B/zh active
- 2019-12-18 EP EP24218737.5A patent/EP4494711A3/en active Pending
- 2019-12-18 KR KR1020217019479A patent/KR102866144B1/ko active Active
- 2019-12-18 IL IL284223A patent/IL284223B2/en unknown
- 2019-12-18 MY MYPI2021003454A patent/MY205718A/en unknown
- 2019-12-18 US US16/719,171 patent/US11149007B2/en active Active
- 2019-12-18 EP EP19901383.0A patent/EP3897636B1/en active Active
- 2019-12-18 SG SG11202106507RA patent/SG11202106507RA/en unknown
- 2019-12-18 HR HRP20250095TT patent/HRP20250095T1/hr unknown
- 2019-12-18 JP JP2021535539A patent/JP7494181B2/ja active Active
- 2019-12-18 PL PL19901383.0T patent/PL3897636T3/pl unknown
- 2019-12-18 KR KR1020257032139A patent/KR20250144505A/ko active Pending
- 2019-12-18 SI SI201930889T patent/SI3897636T1/sl unknown
-
2021
- 2021-06-18 ZA ZA2021/04200A patent/ZA202104200B/en unknown
- 2021-06-18 CL CL2021001665A patent/CL2021001665A1/es unknown
- 2021-06-18 CO CONC2021/0007973A patent/CO2021007973A2/es unknown
- 2021-08-16 US US17/403,742 patent/US11873283B2/en active Active
-
2023
- 2023-11-28 US US18/521,663 patent/US12404241B2/en active Active
-
2024
- 2024-05-22 JP JP2024083009A patent/JP7724911B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12404241B2 (en) | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | |
| US12103920B2 (en) | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | |
| KR102864064B1 (ko) | 치환된 3-((3-아미노페닐)아미노)피페리딘-2,6-디온 화합물, 이의 조성물, 및 이를 사용한 치료 방법 | |
| JP2024526191A (ja) | セレブロン結合化合物、その組成物及びそれによる治療方法 | |
| HK40061385B (en) | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | |
| HK40061385A (en) | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | |
| EA044376B1 (ru) | Соединения замещенного 3-((3-аминофенил)амино)пиперидин-2,6-диона, их композиции и способы лечения с их помощью | |
| JP2024526182A (ja) | セレブロン結合化合物、その組成物及びそれによる治療方法 | |
| JP2024526192A (ja) | セレブロン結合化合物、その組成物及びそれによる治療方法 |